Fibrobiologics, Common Stock Stock Cash Flow From Operations
| FBLG Stock | 2.01 0.14 6.51% |
FibroBiologics, Common Stock fundamentals help investors to digest information that contributes to FibroBiologics, Common's financial success or failures. It also enables traders to predict the movement of FibroBiologics, Stock. The fundamental analysis module provides a way to measure FibroBiologics, Common's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to FibroBiologics, Common stock.
FibroBiologics, | Cash Flow From Operations |
FibroBiologics, Common Stock Company Cash Flow From Operations Analysis
FibroBiologics, Common's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current FibroBiologics, Common Cash Flow From Operations | (6.4 M) |
Most of FibroBiologics, Common's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, FibroBiologics, Common Stock is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
FibroBiologics, Cash Flow From Operations Driver Correlations
Understanding the fundamental principles of building solid financial models for FibroBiologics, Common is extremely important. It helps to project a fair market value of FibroBiologics, Stock properly, considering its historical fundamentals such as Cash Flow From Operations. Since FibroBiologics, Common's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of FibroBiologics, Common's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of FibroBiologics, Common's interrelated accounts and indicators.
Click cells to compare fundamentals
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, FibroBiologics, Common Stock has (6.4 Million) in Cash Flow From Operations. This is 101.21% lower than that of the Biotechnology sector and 110.24% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 100.66% higher than that of the company.
FibroBiologics, Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses FibroBiologics, Common's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of FibroBiologics, Common could also be used in its relative valuation, which is a method of valuing FibroBiologics, Common by comparing valuation metrics of similar companies.FibroBiologics, Common is currently under evaluation in cash flow from operations category among its peers.
FibroBiologics, Common ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, FibroBiologics, Common's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to FibroBiologics, Common's managers, analysts, and investors.Environmental | Governance | Social |
FibroBiologics, Fundamentals
| Return On Equity | -2.68 | ||||
| Return On Asset | -0.66 | ||||
| Current Valuation | 68.6 M | ||||
| Shares Outstanding | 34.66 M | ||||
| Shares Owned By Insiders | 23.56 % | ||||
| Shares Owned By Institutions | 15.83 % | ||||
| Number Of Shares Shorted | 2.7 M | ||||
| Price To Book | 27.35 X | ||||
| EBITDA | (15.9 M) | ||||
| Net Income | (16.48 M) | ||||
| Total Debt | 1.75 M | ||||
| Book Value Per Share | 0.08 X | ||||
| Cash Flow From Operations | (6.4 M) | ||||
| Short Ratio | 13.56 X | ||||
| Earnings Per Share | (0.55) X | ||||
| Target Price | 12.75 | ||||
| Number Of Employees | 10 | ||||
| Market Capitalization | 74.86 M | ||||
| Total Asset | 11.82 M | ||||
| Retained Earnings | (24.36 M) | ||||
| Working Capital | 32 K | ||||
| Net Asset | 11.82 M |
About FibroBiologics, Common Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze FibroBiologics, Common Stock's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of FibroBiologics, Common using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of FibroBiologics, Common Stock based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether FibroBiologics, Common is a strong investment it is important to analyze FibroBiologics, Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact FibroBiologics, Common's future performance. For an informed investment choice regarding FibroBiologics, Stock, refer to the following important reports:Check out FibroBiologics, Common Piotroski F Score and FibroBiologics, Common Altman Z Score analysis. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics, Common. If investors know FibroBiologics, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.55) | Return On Assets (0.66) | Return On Equity (2.68) |
The market value of FibroBiologics, Common is measured differently than its book value, which is the value of FibroBiologics, that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics, Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics, Common's market value can be influenced by many factors that don't directly affect FibroBiologics, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.